In 2019 the pharmaceutical industry saw several large buyouts, including Bristol-Myers Squibb’s $74 billion purchase of Celgene, and AbbVie’s plan to acquire Allergan in a cash and stock deal valued at $63 billion.
But next year, the industry will probably go after single drugs as “bolt-ons,” according to Barry Cohen, an investment guru with 40 years experience in senior positions at large pharma companies, including Abbott and Bayer.
One example of a bolt-on, or relatively smaller deal, is Amgen’s recent $13.4 billion acquisition of Celgene’s psoriasis drug Otezla.
The trend toward these smaller purchases is a result of several factors, including that major pharmaceutical companies have seen slow growth or even a decline in stock prices as well as more antitrust scrutiny, according to the report. The threat of new competition and loss of patent protection also may contribute to the trend of smaller deals, Mr. Cohen wrote.
Read the full report here.
More articles on pharmacy:
Amazon’s PillPack seeking to win over new insurers in 2020
Roche buys international rights to Sarepta’s Duchenne drug for $750M
Former Aegerion sales rep defrauded insurers, stole identities to push cholesterol drug
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
